New longer-term data for elotuzumab showed continued progression-free survival benefit in patients with relapsed or refractory multiple myeloma

ELOQUENT-2 trial, the open-label phase III study randomised 646 patients with relapsed/refractory multiple myeloma to elotuzumab in combination with lenalidomide and dexamethasone (ERd) (n = 321) or… Source link